Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in t...
| FATE | Peers | Sector | |
|---|---|---|---|
Market Cap | 157 M | 98.095 M | 64.214 M |
Price % of 52 Week High | 23.1% | 49.7% | 60.7% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -36.6% | -10.3% | -0.7% |
1 Year Price Total Return | -69.8% | -40.0% | -12.1% |
Beta (5 Year) | 2.42 | 1.15 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 96 | 64 | 14 | 1.68 | 1.86 |
| Operating Income | (308) | (191) | (196) | (48) | (47) |
| Net Profit | (282) | (161) | (186) | (44) | (52) |
| Diluted EPS | -2.91 | -1.64 | -1.64 | -0.45 | -0.44 |
| EBITDA | (295) | (172) | (177) | (43) | (42) |
| Balance Sheet | |||||
| Cash & ST Invest. | 436 | 315 | 279 | 315 | 279 |
| Current Assets | 502 | 332 | 292 | 332 | 292 |
| Total Assets | 706 | 506 | 441 | 506 | 441 |
| Current Liabilities | 114 | 39 | 39 | 39 | 39 |
| Total Liabilities | 222 | 138 | 122 | 138 | 122 |
| Total Equity | 484 | 368 | 319 | 368 | 319 |
| Total Debt | 109 | 104 | 85 | 104 | 85 |
| Cash Flow Statement | |||||
| Cash Flow Operations | (248) | (132) | (123) | (37) | (28) |
| Cash From Investing | 167 | 113 | 12 | 45 | 23 |
| Cash From Financing | 9.21 | 0.09 | 100 | (0.18) | 3.13 |
| Free Cash Flow | (284) | (138) | (124) | (37) | (28) |